You reached the number you were chasing. The clothes fit differently, the bloodwork looks better, and for the first time in a long while the appetite that ran the show has gone quiet.
Then comes the harder question — the one nobody warns you about at the start. What now.
Because the trials are blunt on this point. Stop the medication cold and the hunger returns, and most of the weight follows it back. For years that left people stuck between two bad options: stay on a full dose forever, or watch the results unravel. Microdosing is the quiet third path. Not a different drug, and not a way to lose faster. It is the smallest amount that holds the line once the hard part is done.
01 · The Problem
Why stopping cold fails
The evidence here is not ambiguous, and it is worth sitting with before choosing any path. Two large withdrawal trials measured exactly what happens when people stop.
In the semaglutide extension study, participants who had lost an average of 17.3 percent of their body weight regained about two thirds of it within a year of stopping. The tirzepatide trial, SURMOUNT-4, was starker still. People switched to placebo regained ground fast, while those who continued treatment held onto their results. Roughly 9 in 10 who stayed on tirzepatide kept most of their loss, compared to fewer than 2 in 10 who stopped.
This is not a story about willpower. Obesity behaves like a chronic condition, and these drugs manage it rather than cure it. Take the signal away and the body drifts back toward its old set point. That single fact is the entire argument for maintenance.
What Happens After You Stop
Body weight trajectory — continuing treatment vs stopping (% change from baseline)
- Continued treatment
- Stopped the drug
Based on the shape of regain reported in the semaglutide extension and SURMOUNT-4 withdrawal analyses.
02 · The Idea
What microdosing actually means
Microdosing means using a small fraction of the standard therapeutic dose — sometimes as little as 0.05 to 0.25 mg of semaglutide weekly, often less than one tenth of a full 2.4 mg dose. The goal changes completely. You are no longer trying to lose. You are trying to hold.
There are two common ways to do it. One is a smaller weekly dose. The other is spacing standard-sized doses further apart — every two to four weeks instead of every week. A 2025 case series found many people kept most of their weight off using the spacing approach, which points to a practical and lower-cost path for the right patient.
Full Dose vs Maintenance Microdose
Typical weekly amounts by phase — semaglutide, mg per week
One honest caveat belongs right here. No microdosing schedule is FDA approved. The agency has cleared only standard titration, and professional bodies have not endorsed the practice. It is an off-label strategy, which means it should only happen under a clinician who knows your full history.
03 · The Science
Why a lower dose can still work
The logic rests on a curve. Weight loss from these drugs is dose dependent, but the benefit flattens as the dose climbs. The jump from a tiny dose to a moderate one buys a lot of appetite control. The jump from moderate to maximum buys far less. That flattening is exactly why a small dose can hold results it could not have produced on its own.
Half-life matters too. Semaglutide clears slowly, with a half-life near 7 days, which makes its effect smooth but slow to adjust. Tirzepatide sits tighter at about 5 days. That difference shapes how a maintenance dose feels and how quickly changes register when your provider tunes it.
The Flattening Response Curve
Appetite and weight effect as dose rises — relative effect 0–100
Illustrative dose-response shape — the curve flattens at higher doses, which is why a small maintenance dose retains much of the effect.
04 · The Payoff
Fewer side effects, lower cost
The appeal of a smaller dose is not only about holding weight. Two of the biggest reasons people quit GLP-1s are side effects and price, and a maintenance microdose can ease both. Stomach side effects are dose driven and tend to fade over time anyway. In one 12-month remote program, the share of tirzepatide users reporting no side effects climbed from 41.6% to 60.3%, and for semaglutide from 53.8% to 67.7%. A gentler maintenance dose keeps that calm rather than reintroducing the rough early weeks.
No Side Effects Reported
% of patients side-effect free over 12 months
- Semaglutide
- Tirzepatide
Monthly Cost by Path
Approximate out-of-pocket ranges, USD
- Semaglutide
- Tirzepatide
05 · The Protocol
How a maintenance phase is built
There is no single blueprint, because the right dose is the lowest one that keeps your appetite and weight steady. That number is found, not prescribed from a chart. Still, the process tends to follow a recognizable shape.
Reach your goal on the standard ladder
Active weight loss happens first, on the normal titration schedule, usually reaching a maintenance dose between week 16 and week 24.
Hold, then step down slowly
Once weight plateaus, the provider may lower the dose or space injections, watching how appetite responds at each step.
Find the floor that still holds
The aim is the smallest amount that keeps results stable. For some that is a low weekly dose, for others a standard dose every few weeks.
Protect the result with habits
Protein intake and resistance training guard metabolic rate and lean mass, which makes any given dose work harder.
Common Maintenance Approaches
| Feature | Lower weekly dose | Spaced standard dose |
|---|---|---|
| Typical pattern | 0.05–0.5 mg weekly | Standard dose every 2–4 weeks |
| Feel | Steady, even signal | Gentle peaks and dips |
| Best suited to | Semaglutide, smooth half-life | Either, budget-minded |
| Main tradeoff | Needs precise compounding | Effect may dip late in cycle |
06 · The Honest Limits
Where caution belongs
Enthusiasm should not outrun evidence. Microdosing for maintenance is promising and increasingly common, but it has not been studied as rigorously as standard dosing, and the data is thinner than the headlines suggest.
Compounded medications carry their own risks. As of early 2025 the FDA had logged over a thousand adverse event reports tied to compounded semaglutide and tirzepatide. Measuring partial doses without proper formulation invites dosing errors. And for anyone with type 2 diabetes, a sub-therapeutic dose may not control blood sugar. None of this makes microdosing reckless. It makes medical supervision non-negotiable.
Holding the Line, on Less
Frequently Asked Questions
This article is for educational purposes only and is not medical advice. GLP-1 medications are prescription drugs that require evaluation and monitoring by a licensed clinician. Microdosing for maintenance is an off-label practice not approved by the FDA and not studied as extensively as standard dosing. Compounded medications carry additional risks. Figures cited reflect STEP, SURMOUNT-4, and related published data current as of mid 2026. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.
Find the Dose That Holds Your Results
Precision maintenance protocols designed around the smallest effective dose — with clinician oversight built in.
Find Your Protocol